Success Metrics

Clinical Success Rate
100.0%

Based on 6 completed trials

Completion Rate
100%(6/6)
Active Trials
0(0%)
Results Posted
50%(3 trials)

Phase Distribution

Ph phase_2
1
17%
Ph phase_3
1
17%
Ph phase_1
4
67%

Phase Distribution

4

Early Stage

1

Mid Stage

1

Late Stage

Phase Distribution6 total trials
Phase 1Safety & dosage
4(66.7%)
Phase 2Efficacy & side effects
1(16.7%)
Phase 3Large-scale testing
1(16.7%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

6 of 6 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

6

all time

Status Distribution
Completed(6)

Detailed Status

Completed6

Development Timeline

Analytics

Development Status

Total Trials
6
Active
0
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 14 (66.7%)
Phase 21 (16.7%)
Phase 31 (16.7%)

Trials by Status

completed6100%

Recent Activity

0 active trials
Showing 5 of 6
completedphase_1

A Study of XL184 (Cabozantinib) With or Without Erlotinib in Subjects With Non-Small Cell Lung Cancer (NSCLC)

NCT00596648
completedphase_2

Study of XL184 (Cabozantinib) in Adults With Glioblastoma Multiforme

NCT00704288
completedphase_3

Efficacy of XL184 (Cabozantinib) in Advanced Medullary Thyroid Cancer

NCT00704730
completedphase_1

Safety Study of XL184 (Cabozantinib) in Combination With Temozolomide and Radiation Therapy in the Initial Treatment of Adults With Glioblastoma

NCT00960492
completedphase_1

A Drug-Drug Interaction Study of the Effects of XL184 (Cabozantinib) on Rosiglitazone in Subjects With Solid Tumors

NCT01100619
View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials
NCT00596648Phase 1

A Study of XL184 (Cabozantinib) With or Without Erlotinib in Subjects With Non-Small Cell Lung Cancer (NSCLC)

Completed
NCT00704288Phase 2

Study of XL184 (Cabozantinib) in Adults With Glioblastoma Multiforme

Completed
NCT00704730Phase 3

Efficacy of XL184 (Cabozantinib) in Advanced Medullary Thyroid Cancer

Completed
NCT00960492Phase 1

Safety Study of XL184 (Cabozantinib) in Combination With Temozolomide and Radiation Therapy in the Initial Treatment of Adults With Glioblastoma

Completed
NCT01100619Phase 1

A Drug-Drug Interaction Study of the Effects of XL184 (Cabozantinib) on Rosiglitazone in Subjects With Solid Tumors

Completed
NCT00215605Phase 1

Study of XL184 (Cabozantinib) in Adults With Advanced Malignancies

Completed

All 6 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
6